index - Myopathies inflammatoires & thérapies innovantes ciblées Accéder directement au contenu

Dernières publications

Chiffres clés

123 Publications avec texte intégral

Open Access

53 %

Mots clés

Anti-IgE IgG Idiopathic inflammatory myopathies Dermatomyositis Fabry disease AAV antibody Pharmacology Antisynthétase Aged Gene therapy Myocarditis B-lymphocyte Abnormal movement Aldosterone Deep immune profiling Muscle Anti-synthetase syndrome AAV vectors Antiphospholipid syndrome Antibody responses COVID-19 Myopathy Machine learning Adult AAV humoral immunity Autoimmunity IBM Anti‐mitochondrial antibodies Humans Skeletal muscle Biopsy Anémie hémolytique Acute Kidney Injury/epidemiology/etiology Immune checkpoint inhibitors Anticorps spécifique des myosites Polymyositis Multidisciplinarity Anti-agalsidase antibodies Autoantibodies Anti-drug antibodies Inborn errors of metabolism Analyses multidimensionnelles Data integration Systems biology Cytokines Adjudication Antibodies Autoantibody Female Biomarkers AAV vector Inclusion body myositis Biomarker Bioelectrical impedance analysis Adolescence Outcome measures Auto-antibodies Anti-MDA5 autoantibodies Adeno-associated vector Anticorps anti-agalsidase Inflammation Myositis AAV Anti-interleukin-6 Middle Aged Amyotrophic lateral sclerosis Sphingosine-1-phosphate Assisted communication devices Immunotherapy Anti-Mi2 Amyotrophy Adverse drug reactions Interstitial lung disease DM Interferon Biomarqueurs Antisynthetase Active IMNM Auto-immunité Case reports Auto‐antibodies Mass cytometry Animals B cell homeostasis Adeno-associated virus Myositis and muscle disease Acid-alpha-glucosidase Adeno-associated virus vector Lysosomal storage diseases Male Cardio-oncology Aldostérone Inflammatory myopathy Dependovirus/genetics/immunology Cancer Autoimmune diseases Arthritis Antisynthetase syndrome Agalsidase Prognosis